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ABSTRACT 
 
RAPADILINO syndrome is an autosomally resessively inherited condition that 
belongs to a group of rare syndromes more common in Finland than in other parts of 
the world. These syndromes are not only characterized by their prevalence in 
Finland, but also by the presence of a common founder mutation. RAPADILINO is 
characterized by pre- and postnatal growth retardation, radial ray defects, diarrhoea 
of unknown aetiology during chilhood, a facial resemblance with other patients and 
normal intelligence. In Finland, 15 patients with this condition have been found 
which compares with only five patients in other parts of the world. 
When mutations in the RECQL4 gene were found in RAPADILINO patients, 
RAPADILINO syndrome was proven to be allelic with a subgroup of Rothmund-
Thomson syndrome (RTS). Later on mutations in patients with Baller-Gerold 
syndrome (BGS) were also found in RECQL4. These syndromes are also 
characterized by pre- and postnatal growth retardation, radial ray defects and 
gastrointestinal problems. Differential diagnostics rely on poikiloderma, which is a 
hallmark feature of RTS found also in BGS patients, but not in RAPADILINO 
syndrome. Craniosynostosis is a feature found in BGS and the narrow definition of 
BGS is craniosynostosis with radial defects. RTS patients with RECQL4 mutations 
have an elevated risk for osteosarcoma, but their risk to develop other types of 
malignancies does not increase. Two Finnish RAPADILINO patients have been 
diagnosed with osteosarcoma. In addition to this we have found an excess of 
lymphoma cases among the Finnish RAPADILINO patients. 
The genotype-phenotype correlation is not straightforward but it seems that 
RAPADILINO could be due to alteration in protein function and truncating 
mutations in both alleles are more common among RTS patients. It has been shown 
that truncating mutations are linked to the osteosarcoma risk seen in RTS. We found 
five different mutations in the Finnish RAPADILINO patients. The g.2545delT 
mutation is the founder mutation in the Finnish population as all the patients are 
either homozygotes or compound heterozygotes for it. This mutation leads to the 
inframe skipping of exon seven from mRNA. The protein encoded by this mutant 
mRNA lacks the nuclear retention signal and thus leads to the mislocalization of the 
mutant protein. 
RECQL4 belongs to the RecQ gene family and there are five different RecQ genes 
in humans. Three of them - RECQL4, BLM and WRN - are linked to human 
syndromes which are characterized by growth retardation, dermatological changes 
and an elevated cancer incidence. Even though the exact role of RECQL4 is 
unknown it is proposed to take part in the maintenance of genomic integrity even if 
it lacks the helical activity that is present in all other RecQ proteins. 
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TIIVISTELMÄ 
RAPADILINO-oireyhtymä on harvinainen suomalaiseen tautiperintöön kuuluva 
autosomaalisesti peittyvästi periytyvä oireyhtymä, joka on Suomessa diagnosoitu 15 
henkilöllä ja muualla maailmassa viidellä potilaalla. Kuten muissakin suomalaisen 
tautiperinnön taudeissa Suomessa RAPADILINO-oireyhtymän taustalla on yksi 
yhteinen perustajamutaatio. Lisäksi on tunnistettu neljä muuta harvinaisempaa 
mutaatiota. RAPADILINO-oireyhtymä on nimetty pääoireidensa mukaan ja niiden 
esiintyvyys ja vakavuusaste vaihtelee potilaiden välillä. Useimmiten potilailla on jo 
ennen syntymää alkanut kasvuhäiriö, joka jatkuu syntymän jälkeen ja johtaa 
pienikasvuisuuteen. Lisäksi heillä on luuston kehityshäiriöitä, kuten puuttuvat tai 
alikehittyneet peukalot, värttinäluut sekä polvilumpiot. Potilaat kärsivät 
lapsuudessaan selittämättömästä syystä johtuvasta ripulista, joka yleensä paranee 
itsestään lasten vanhentuessa. Potilailla ei ole henkistä jälkeenjääneisyyttä ja he 
muistuttavat toisiaan enemmän kuin terveitä sisaruksiaan. 
RAPADILINO-oireyhtymän taustalta löytyivät mutaatiot RECQL4-geenissä, jonka 
mutaatioiden tiedettiin aiheuttavan osan Rothmund-Thomson –oireyhtymän 
tapauksista. Myöhemmin löysimme saman geenin mutaatiot myös Baller-Gerold –
oireyhtymää sairastavilta potilaita. Nämä oireyhtymät ovat oireistoltaan osittain 
samanlaisia, sillä kaikkiin kuuluu kasvuhäiriö, peukaloiden, värttinäluiden sekä 
polvilumpioiden puuttuminen tai alikehittyneisyys. Erottavina piireitä ovat 
poikilodermaksi kutsuttu tyypillinen ihottuma RTS- ja BGS-potilailla sekä 
kraniosynostasia eli kallonluiden liian aikainen sulkeutuminen BGS-potilailla. Niillä 
RTS-potilailla, joilla on mutaatiot RECQL4-geenissä, on kohonnut riski sairastua 
pahanlaatuiseen luusyöpään, osteosarkoomaan. Suomalaisista RAPADILINO-
potilaista kaksi on sairastanut osteosarkooman, ja tutkimuksessamme olemme myös 
havainneet suomalaisilla potilailla kohonneen lymfoomariskin. 
Ilmiasun ja RECQL4-mutaatioiden välillä ei ole täydellistä yhteyttä, mutta 
RAPADILINO-oireyhtymää sairastavilla on useimmiten ainakin toisena 
mutaationaan sellainen muutos, joka ei aiheuta geenin lukukehyksen tuhoutumista 
tai ennenaikaista katkeamista. Tällaisia ennenaikaisia lopetuskodoneita tai 
lukukehyksen sekoittavia mutaatioita löytyy useimmiten RTS-potilaita ja niiden ja 
osteosarkooman välillä on havaittu yhteys. Suomalaisilla RAPADILINO-potilailla 
g.2545delT mutaatio aiheuttaa mRNA:n silmikoitumishäirön, joka johtaa eksonin 
seitsemän koodaaman alueen puuttumiseen mRNA:sta, muttei kuitenkaan tuhoa 
lukukehystä. Näin syntynyt mutanttiproteiini päätyy solussa solulimaan tuman 
sijasta, sillä siitä puuttuu tarvittava tumassapitosignaali. 
RECQL4-proteiinin toimintaa ei tunneta vielä kunnolla, mutta se ilmeisesti toimii 
genomisen vakauden ylläpitäjänä muiden RecQ-proteiinien tavoin. RECQL4 kuuluu 
RecQ-geeniperheeseen johon ihmisellä kuuluu viisi geeniä - RECQL, BLM, WRN, 
RECQL4 ja RECQL5. Mutaatiot RECQL4-, BLM- ja WRN-geeneissä aiheuttavat 
perinnöllisiä oireyhtymiä, joita yhdistävät ihomuutokset, pienikasvuisuus sekä 
syöpäalttius. 
Avansanat: RAPADILINO-oireyhtymä, Rothmund-Thomson -oireyhtymä, Baller-
Gerold -oireyhtymä, RECQL4-geeni, RecQ-geeniperhe, osteosarkooma, lymfooma 
 
CONTENTS 
Abbreviations............................................................................................................... 13 
List of original publications..................................................................................... 15 
1 Introduction.......................................................................................................... 16 
2 Review of the literature .................................................................................... 17 
2.1 FINNISH DISEASE HERITAGE .....................................................................17 
2.2 POSITIONAL CLONING...............................................................................17 
2.3 RAPADILINO SYNDROME ......................................................................20 
2.4 ROTHMUND-THOMSON SYNDROME..........................................................21 
2.4.1 Subgroup of Rothmund-Thomson syndrome with RECQL4 
mutations ......................................................................................... 23 
2.5 BALLER-GEROLD SYNDROME...................................................................26 
2.6 RECQL4 GENE AND PROTEIN ...................................................................26 
2.6.1 RecQ gene family and helicases ...................................................... 28 
2.6.1.1. Bloom and Werner syndromes ................................................ 29 
2.6.2 Possible role and function of the RECQL4 protein ......................... 31 
2.6.3 Recql4 deficient mouse models........................................................ 32 
3 Aims of the study................................................................................................. 34 
4 Patients, Materials and methods.................................................................... 35 
4.1 PATIENTS AND DNA SAMPLES .................................................................35 
4.2 CELL LINES ...............................................................................................35 
4.3 METHODS PRESENTED IN ARTICLES..........................................................36 
4.4 OTHER METHODS......................................................................................36 
4.4.1 Recombination and physical map of markers adjacent to 
RECQL4 .......................................................................................... 36 
4.4.2 DNA extraction from paraffin embedded blocks ............................. 36 
4.4.3 Cloning of the RECQL4 constructs ................................................. 37 
4.4.4 Antibody production ........................................................................ 38 
4.4.5 Transfection of the cells................................................................... 39 
4.4.6 Immunostaining ............................................................................... 39 
4.4.7 Confocal microscopy ....................................................................... 40 
5 Results and discussion ...................................................................................... 41 
5.1 GENOTYPING (I) .......................................................................................41 
5.2 SEQUENCING OF THE RECQL4 GENE (I, II, III, IV)...................................45 
5.2.1 RECQL4 mutations in Finnish RAPADILINO patients ................... 45 
5.2.2 Minisequencing of controls and patients with pre- or postnatal 
growth retardation........................................................................... 46 
5.2.3 RECQL4 mutations in Rothmund-Thomson, Baller-Gerold and 
non-Finnish RAPADILINO patients ................................................ 47 
5.2.4 The amino acid changes in the RECQL4 protein ............................ 49 
5.3 PHENOTYPES OF RECQL4 SYNDROME PATIENTS AND THE GENOTYPE-
PHENOTYPE CORRELATION (I, II, III, IV) ..................................................50 
5.4 CANCER PREDISPOSITION IN RECQL4 SYNDROMES .................................53 
5.5 IN SITU HYBRIDISATION (I)........................................................................54 
5.6 CELL LINES (I, UNPUBLISHED) ..................................................................55 
5.7 RECQL4 CONSTRUCTS AND THE RESULTS OF TRANSFECTIONS 
(UNPUBLISHED) ........................................................................................55 
6 Conclusion............................................................................................................. 58 
7 Acknowledgements ............................................................................................ 59 
8 References............................................................................................................. 61 
 
13 
ABBREVIATIONS   
ATP Adenosine triphosphate 
BGS Baller-Gerold syndrome 
BLM Bloom syndrome 
bp base pair 
cM centiMorgan 
DSB Double strand breaks  
DNA Deoxyribonucleic acid 
GTP Guanosine triphosphate 
HR Homologous recombination 
HRDC Helicase-and-ribonuclease D/C-terminal 
HU Hydroxyurea 
kb kilobase pair 
LD Linkage disequilibrium 
Mb megabase pair 
MIM Mendelian inheritance in man 
NHJ Nonhomologous end-joining 
OS Osteosarcoma 
PCR Polymerase chain reaction 
PMA Phorbol myristic acetate 
PML  Promyelotic leukemia 
Rad51 Homolog of RecA of E. coli 
RNA Ribonucleic acid 
RECQL RecQ like 
RECQL4 RecQ like 4 
RECQL5 RecQ like 5 
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RQC RecQ conserved region 
RTS Rothmund-Thomson syndrome 
SCE Sister chromatin exchange 
SGA  Small for gestational age 
SNP Single nucleotide polymorphism  
TDT-LRT Transmission disequilibrium test - likelihood ratio test 
UBR1 Ubiquitin-protein ligase E3 component N-recognin 1 
UBR2 Ubiquitin-protein ligase E3 component N-recognin 2 
WRN Werner syndrome 
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1 INTRODUCTION 
RAPADILINO syndrome is a rare condition found mainly in Finland, but some 
patients are found also in other parts of the world. RAPADILINO syndrome is 
characterized by growth retardation (>-2SD) and bone malformations such as hypo- 
or aplasia of the thumbs, radius and patellae. Other clinical findings include 
diarrhoea, typical facial features, joint dislocations and normal intelligence. 
RAPADILINO syndrome is caused by mutations in the RECQL4 gene. Ten Finnish 
patients were found to be homozygotes for the g.2545delT mutation (Finmajor) and 
five others were compound heterozygotes for this and another mutation. The Finnish 
founder mutation leads to inframe skipping of exon 7 and the four other mutations in 
Finnish population were truncating mutations. 
Mutations in the RECQL4 gene cause not only RAPADILINO, but also Rothmund-
Thomson (RTS) and Baller-Gerold (BGS) syndromes. These three RECQL4 
syndromes have overlapping clinical findings such as growth retardation and radial 
ray defects, but poikiloderma and craniosynostosis are the hallmarks of their 
differential diagnostics. Patients share similar symptoms, but the syndromes are 
classified as separate diseases because of their different clinical findings. Patients 
with Rothmund-Thomson and Baller-Gerold syndromes have not been reported in 
Finland. In total 48 RECQL4 mutations have been found, most of them being 
truncating mutations such as insertions, deletions, premature stop codons and splice 
site mutations. In general the genotype has a strong tendency to predict the 
phenotype, but it is not conclusive and this makes a thorough understanding of the 
RECQL4 spectrum phenotypes demanding, but also rewarding. 
For a long time RAPADILINO syndrome was thought to be a rare syndrome, only 
present in the isolated Finnish population. Yet it became an interesting example of a 
syndrome in which specific genetic defects lead to a distinct phenotype. When 
RAPADILINO and RTS were shown to be allelic the difference in the osteosarcoma 
incidence between these two syndromes was striking. Osteosarcoma has been reported 
to be much more common among RTS patients than in RAPADILINO patients. In 
addition to two osteosarcoma cases four Finnish RAPADILINO patients were found 
to develop lymphomas not described in RTS patients. This finding emphasizes the 
unique role of RECQL4 at the cellular level. RECQL4 is known to have high 
expression in chondrocytes, and skeletal defects with the elevated osteosarcoma 
incidence made it clear that RECQL4 plays an important role in the developing bone. 
Because RAPADILINO patients are prone to lymphoma it can be assumed that 
RECQL4 would have important functions in haematological cells as well. 
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2 REVIEW OF THE LITERATURE 
2.1 Finnish disease heritage 
The Finnish disease heritage is a group of 36 inherited conditions that are more 
common in Finland than in any other parts of the world (findis.org) (Perheentupa, 
1972). These are all rare monogenic syndromes and 32 of them are recessive, two 
dominant and two X-linked (Norio, 2003c). The reason for this unique set of 
diseases in Finland is pure chance and the population history of this isolated country. 
(Norio, 2003b). On the other hand some diseases for example phenylketouria and 
cystic fibrosis that are common elsewhere are virtually nonexistent in Finland  
(Guldberg, et al., 1995; Kere, et al., 1994).  
The molecular background of the diseases of the Finnish disease heritage has been 
effectively studied since the 1980’s and the genetic defects underpinning all of these 
syndromes except Peho syndrome (Salonen, et al., 1991) are now known. In all the 
cases one prevalent founder mutation has been found to have the main contribution 
to the disease. In most diseases more than 90% of the Finnish patients have the same 
Finmajor mutation (Norio, 2003c). However, in some diseases the frequency of the 
Finmajor mutation is only about 70-80% and several minor mutations have been 
identified in Finnish and foreign patients, see e.g. (Huopaniemi, et al., 1999; Kestilä, 
et al., 1998; Kure, et al., 1992; Nagamine, et al., 1997; Sankila, et al., 1992). 
2.2 Positional cloning 
Isolated populations have been proven to be very useful in a disease gene hunting, 
for a review see e.g. (de la Chapelle and Wright, 1998; Norio, 2003c; Peltonen, et 
al., 1999). If the clinical examination is done thoroughly and the diagnostic criterion 
is kept strict enough there is a great probability that there is a common genetic 
defect behind the phenotype when studying isolated populations. But however it is 
possible that a same phenotype can be caused mutations in different genes 
(Paloneva, et al., 2000; Paloneva, et al., 2002). Church records in Finland are well 
kept and since they cover a long time span genealogical studies can also reveal 
common ancestors among the patients and thus confirm the assumption of a shared 
genetic background (Norio, 2003a).  
In order to identify a disease-causing gene one first needs to collect DNA samples 
from the patients, their siblings and parents and genotype them by using a genome 
wide scan. From the genotype data one gets potential linkage to a genomic region 
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where the genetic defect can be found. Now when the human genome project has 
been completed and the genetic data is available in databases the positional cloning 
of the gene has become significantly easier and faster than earlier (Lander, et al., 
2001; Venter, et al., 2001). However, in many cases the workflow is not as smooth 
and straightforward as it should be in theory. One of the restricting factors may be 
low numbers of samples if there are only a few patients with no siblings or samples 
from the patients’ families are unavailable.  
Because of the naturally occurring genetic variations between individuals 
genotyping them is possible (Botstein, et al., 1980). Nowadays in whole genome 
studies one can use either microsatellite markers (Dubovsky, et al., 1995) or single 
nucleotide polymorphisms (SNPs) (Frazer, et al., 2007)  to get data for the study. 
Microsatellite markers are repetitive sequencies where the same nucleotide 
combination is repeated several times. Di, tri and tetra nucleotide repeats are the 
most common repeat types. The best microsatellite markers are those that have 
several different alleles in the population. Hundreds of microsatellite markers are 
used in genome wide studies to detect linkage (Dubovsky, et al., 1995). If linkage is 
found in the initial screening, the chromosomal area can be further studied with 
additional markers. SNPs are polymorphisms of a single nucleotide that usually have 
no phenotypic effect (www.hapmap.org/). The numbers of SNPs detectable in the 
human genome is approximately 10 million. However, a smaller set of SNPs (e.g. 
500 000) is big enough for genome wide studies. Certain SNP combinations occur 
together in so called haplotype blocks and these blocks can be identified by using 
tag SNPs. The human genome contains approximately 300 000 to 600 000 tag SNPs 
(www.hapmap.org/). 
A combination of alleles of adjacent markers forms a haplotype and the haplotype is 
transmitted from one generation to the next. However, the haplotype becomes 
shorter, because recombinations occur between homologous chromosomes in 
meiosis. Thus in principle the older the ancestral haplotype is the shorter it has 
become. However, there are differences in the recombination probabilities in 
different parts of genome and in so called recombination hot spots the 
recombinations occur more often than in chromosomes in general (Broman, et al., 
1998). Thus if a recombination hot spot is located in the studied chromosomal area 
the haplotype becomes shorter rapidly. 
This phenomenon is explained in Figure 1 where the shortening of the original white 
chromosomal area after a series of recombinations can be seen. The founder 
mutation that emerges into the ancestral chromosome has been marked with a star. 
The number of patients and the size of families have a significant consequence since 
the more chromosomes there are to study the more likely informative 
recombinations can be observed.  
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Figure 1. Possible outcome of recombinations in a founder chromosome after series 
of recombination. 
 
When the genotype data from the families is available one can start to find shared 
regions between the patients. If patients share a common genomic area they seem to 
have certain alleles of the microsatellite markers more often than would be expected 
thus the genetic defect is linked to certain alleles of the markers. The closer the 
genetic defect and a marker are to each other the more likely they are to appear 
together from one generation to the next. This phenomenon is called linkage 
disequilibrium (LD) and usually getting linkage to a certain region over 1 cM in size 
by chance is low, but not impossible  (Peterson, et al., 1995; Thompson and Neel, 
1997). For example in monogenic diseases where a common founder mutation is 
expected one needs to find genomic areas where patients have the same haplotype. 
In dominant diseases the patients share the same haplotype in one of their 
chromosomes. In recessive disorders a mutation has to be present in both 
chromosomes. If patients are homozygotes for the mutation they usually share the 
same haplotype in their both chromosomes. In cases where patient is compound 
heterozygote for the founder mutation they have one chromosome that bears the 
common founder haplotype. Their second chromosome has a different haplotype 
since it is derived from a different ancestral chromosome.  
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In the diseases of the Finnish disease heritage the shared haplotype is usually long 
and the linkage disequilibrium can be detected over a several cM interval as for 
example in Northern epilepsy (Tahvanainen, et al., 1994). This of course makes the 
choice of candidate genes difficult, as there can still be tens of genes in the shared 
haplotype area. If the function of the genes are known or can be predicted the choice 
may be easy, but in some cases there is a tedious task of sequencing ahead.  
2.3 RAPADILINO syndrome 
The RAPADILINO syndrome (MIM 266280) is a rare autosomally recessively 
inherited disorder that is enriched in the Finnish population. The clinical findings in 
the first five patients prompted the clinicians to name this syndrome after the main 
manifestations which were RAdial and PAtellar hypo- or aplasia, high arched or 
cleft PAlate, DIslocation of joints and DIarrhoea of unknown origin, LImb 
malformations and LIttle size, long and slender NOse and NOrmal intelligence 
(Kääriäinen, et al., 1989). The patients have normal hair, eybrows and eyelashes and 
their only dermatological feature is brownish spots resembling irregularly shaped 
café-au-lait spots (Kääriäinen, et al., 1989).  
After this initial report three cases have been described outside Finland (Jam, et al., 
1999; Kant, et al., 1998; Vargas, et al., 1992). All these patients had classical 
features of RAPADILINO and in two cases the phenotypes were compared to other 
similar phenotypes for differential diagnostics (Kant, et al., 1998; Vargas, et al., 
1992). RAPADILINO was thus assumed to be present also in other parts of the 
world and not to be a syndrome found only in Finland. Later, one non-Finnish 
patient was re-diagnosed to suffer from Rothmund-Thomson syndrome (Hilhorst-
Hofstee, et al., 2000; Kant, et al., 1998). The clinical picture of seven 
RAPADILINO patients is shown in Table 1. Since strict criteria was used, patients 
have very similar phenotypes although rare findings such as malsegmentation of 
cervical spine and brownish spots on skin were also reported (Jam, et al., 1999; 
Kant, et al., 1998; Kääriäinen, et al., 1989).  
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Table 1. Clinical data from seven RAPADILINO patients 
 1 2 3 4 5 6 7 
Short stature + + + + + + + 
Hypoplastic or absent radius + + + + + + + 
Hypoplastic or absent thumb + + + + + + + 
Hypoplastic or absent patellae + + + + + + + 
Joint dislocation - + + - + - + 
Cleft or high arched palate + + + + + + + 
Diarrhoea + + + + + + + 
Normal intelligence + + + + + + + 
Typical face + + + + + + + 
High pitched voice + + + + + + + 
Brownish spots  + - - - - * - 
Patients 1 to 5 are the first RAPADILINO patients described (Kääriäinen, et al., 
1989). Patient 6 is the first non-Finnish patient (Vargas, et al., 1992) and patient 7 
the second non-Finnish RAPADILINO case (Jam, et al., 1999).  
* Patient has a dark skin color so brownish spots would not be visible. 
2.4 Rothmund-Thomson syndrome 
Originally, the Rothmund-Thomson syndrome (RTS, MIM 268400) was actually 
two separate entities described by Rothmund (Rothmund, 1887) and Thomson 
(Thomson, 1936). Rothmund’s eight patients were from three families from an 
isolated Bavarian alpine valley (Rothmund, 1887). Thannhauser (1945) gives an 
English translation of the clinical descriptions in Rothmund’s original 1887 article 
and also reviews the literature of possible Rothmund syndrome patients 
(Thannhauser, 1945). The patients described by Rothmund had similar overall 
appearance and their mental and physical development was normal. All of these 
patients had poikiloderma, and most of them had bilateral juvenile cataract. Later 
some of these patients were re-evaluated and only one of them was short, had small 
hands and feet and short extremities. Her hair started to grey and fall off and at the 
age of 40 she was bald (Thannhauser, 1945). Some decades later Thomson described 
three British patients who suffered from poikiloderma (Thomson, 1936). Two of the 
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patients were siblings so in their case a common genetic defect was the most likely 
explanation. However, there was a striking phenotypic difference between the 
siblings since the first one had only poikiloderma and a skeletal X-ray study 
revealed only slight disproportion in the skull bones giving her face a triangular 
appearance. The second sibling had poikiloderma accompanied by growth 
retardation and radial ray defect. She died at the age of one year because of an 
unknown cause. The third patient was a separated case with poikiloderma, but no 
striking bone anomalies. She had sparse hair, eyebrows and eyelashes and a facial 
resemblance with the first patient. None of these patients developed juvenile 
cataract. In both families the mode of inheritance was proposed to be autosomal 
recessive. Rothmund and Thomsons’ syndromes were later combined into one entity 
and poikiloderma was chosen to be the hallmark feature (Taylor, 1957). 
Approximately 200 RTS cases are described in the literature (Vennos, et al., 1992). 
Poikiloderma is a rash that is characterized by its acute and chronic phase (Vennos and 
James, 1995). In the beginning edematous plaques or eryhematosus patches appear on 
the cheeks and then start to spread to the extremities usually sparing the trunk. After 
the acute phase, the skin develops the typical poikilodermic appearance. It includes 
hypo- and hyperpigmented areas with atrophy and telengiactesia i.e. the widening of 
the capillaries (Thomson, 1936; Vennos, et al., 1992). Both sensitivity and 
insensitivity to the light has been reported and some patients have blistering of the skin 
during the acute phase. There are many syndromes which have poikiloderma like 
features or true poikiloderma as one of the symptoms (German and Takebe, 1989; 
Siegel, et al., 2003; Wang, et al., 2003a). Skin biopsies and histological examinations 
can be helpful to determine the type of dermatological changes. In RTS, poikiloderma 
usually appears at the age of three to six months and it has the typical pattern and 
distribution starting from the face and then spreading to the extremities (Vennos, et al., 
1992). Later onset of poikiloderma at the age of one to three years is rare and these 
patients are considered to have atypical RTS (Wang, et al., 2003b). 
As poikiloderma is the only constant finding in RTS patients large amount of 
additional symptoms have been reported in these patients. These findings include for 
example radial ray defects, growth retardation, cataract, alopecia, gastrointestinal 
findings and malignancies, mainly osteosarcomas (Moss, et al., 1990; Starr, et al., 
1985; Wang, et al., 2001; Vennos, et al., 1992). In some patients chromosomal 
instability and defect in DNA repair has been found (Der Kaloustian, et al., 1990; 
Miozzo, et al., 1998; Orstavik, et al., 1994), but not in others (Dick, et al., 1982; 
Shuttleworth and Marks, 1987; Starr, et al., 1985). The differences in clinical 
findings suggest that RTS is a genetically heterogeneous syndrome.  
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2.4.1 Subgroup of Rothmund-Thomson syndrome with RECQL4 
mutations 
Finding of mutations in the RECQL4 gene from a subset of RTS patients proved the 
genetic heterogeneity in RTS (Kitao, et al., 1999b). Further mutation screenings 
among RTS patients have confirmed the initial finding (Balraj, et al., 2002; Beghini, 
et al., 2003; Broom, et al., 2006; Lindor, et al., 2000; Sznajer, et al., 2008; Wang, et 
al., 2003a; Wang, et al., 2003b; Wang, et al., 2002). In the most comprehensive 
study approximately 70% of the studied RTS patients had RECQL4 mutations and 
most of them were truncating mutations (Wang, et al., 2003b).  
Clinical data from the patients with RECQL4 mutations is limited, but it gives clues 
which phenotypic features are most common among these patients. Usually patients 
have prenatal growth retardation, radial ray defects, alopecia, loss of eyebrows and 
eyelashes, gastrointestinal problems and osteosarcoma in addition to poikiloderma. 
None of the patients have developed bilateral juvenile cataract.  
In this light it seems evident that patients described by Rothmund and Thomson very 
likely suffered from different clinical entities. Any patient with poikiloderma can 
potentially have RTS, but the major problem is that poikiloderma is not a specific 
feature. If the result of the differential diagnosis is RTS determining the subgroup 
might prove important because of the elevated osteosarcoma risk in RTS patients 
with RECQL4 mutations. It has been suggested that Rothmund-Thomson syndrome 
should be separated into the RTSI and RTSII subtypes (Wang, et al., 2003b). 
Patients described by Rothmund (Thannhauser, 1945) represent the RTSI phenotype 
while patients with RECQL4 mutations have the RTSII phenotype (Wang, et al., 
2003b). According to Wang’s classification a patient with atypical poikiloderma 
either in the form of distribution or the age of onset should have two additional 
features to substantiate the RTS diagnosis. These findings would be growth 
retardation, radial ray defects or skeletal dysplasia, osteosarcoma, cataract, alopecia 
or loss of eyebrows and eyelashes (Wang, et al., 2003b). It is peculiar that cataract is 
in the diagnostic criteria since bilateral juvenile it is not found in patients with 
RECQL4 mutations (Balraj, et al., 2002; Beghini, et al., 2003; Broom, et al., 2006; 
Hilhorst-Hofstee, et al., 2000; Kant, et al., 1998; Kitao, et al., 1999b; Lindor, et al., 
1996; Lindor, et al., 2000; Miozzo, et al., 1998; Pujol, et al., 2000; Sznajer, et al., 
2008; Tong, 1995; Wang, et al., 2003b; Volpi, 2004). 
RTSII phenotype is associated with elevated risk for osteosarcomas, but peculiarly 
not for other malignancies (Wang, et al., 2003b). Interestingly, RECQL4 mutations 
do not seem to contribute to sporadic osteosarcoma (OS) cases (Nishijo, et al., 
2004). RTSII patients develop osteosarcoma at a younger age than the patients in 
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sporadic cases, but their response to the treatment were not different from the 
sporadic cases (Hicks, et al., 2007). Only two RTS patient with the RECQL4 
mutations have developed another type of malignancy and both patients developed 
osteosarcoma first (Wang, et al., 2003b). Additionally, some patients have signs of 
the chromosomal instability, but these findings are not consistent (Broom, et al., 
2006; Miozzo, et al., 1998). 
Clinical data from the RTS patients with known RECQL4 mutations and from two 
RTS cohorts are presented in Table 2. The first row contains data from 10 patients 
with the confirmed RECQL4 mutations. A symptom was assumed to be absent if it 
was not given in the clinical data. This of course can lead to minor inaccuracies in 
the results as some of the features have been probably been unreported even if they 
were present. It is apparent that there is some overlap in described cases between 
these three groups (Table 2). For example some of the patients in the cohort of 41 
patients likely belong to group of 10 RTS patients with RECQL4 mutations. 
Additional features such as anal artresia, hearing loss, chromosomal instability, 
osteoporosis and problems with immunity are found occasionally. So far none of the 
patients has developed bilateral juvenile cataract. Some of the patients have 
irregularly shaped brownish spots and one of them has hyperpigmentation in the 
trunk which follows the lines of Blashchko (Broom, et al., 2006).  
In the London medical database (www.lmdatabases.com/) craniosynostosis is listed as 
one of the features of RTS apparently based on the findings of Mégarbane and co-
workers (Megarbane, et al., 2000).  The patient was diagnosed with Baller-Gerold 
syndrome, but the clinical finding was also consistent with RTS. Craniosynostosis 
may have been unreported in some cases since Lisa Wang and Sharon Plon (personal 
communication) reported craniosynostosis in some cases of their RTS patients. 
Unfortunately, it is not known which of these patients had RECQL4 mutations. 
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Table 2. Clinical data from three different sets of RTS patients.  
 Po
ik
ilo
de
rm
a 
Sh
or
t s
ta
tu
re
 
Th
um
b 
an
om
al
y 
R
ad
iu
s a
no
m
al
y 
Pa
te
lla
r d
ef
ec
t 
Pa
la
ta
l d
ef
ec
t 
O
st
eo
sa
rc
om
a 
G
I p
ro
bl
em
s 
A
lo
pe
ci
a/
ha
ir 
lo
ss
 
Sp
ar
se
 b
er
ow
s 
an
d 
la
sh
es
 
10 patients 
with 
RECQL4 
mutations  
 
100 
 
90 
 
50 
 
30 
 
20 
 
10 
 
70 
 
20 
 
20 
 
40 
202 RTS 
cases from 
literature 
 
100 
 
70 
 
27# 
 
- 
 
- 
 
* 
 
- 
 
80## 
Cohort of 
41 RTS 
patients 
 
100  
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** 
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32 
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The values are given in percentages. In the first row the percentages are suggestive 
since the clinical data available was more thorough in some reports than in others. 
In the cohort of 41 patients the percentages are counted from the patients whose 
information was available; for example growth retardation was seen in 25 patients 
and this data was available from 38 of 41. 
# Thumb anomaly and radius anomaly combined. ## Alopecia/hairloss and sparse 
eyebrows and eyelashs combned.* The authors state that the estimation of the 
frequency is difficult and that there were nine osteosarcoma cases in the literature 
(Wang, et al., 2001; Vennos and James, 1995). ** Found in some cases. 
Clinical and mutational data was collected from the following publications (Balraj, 
et al., 2002; Beghini, et al., 2003; Broom, et al., 2006; Kitao, et al., 1999b; Lindor, 
et al., 1996; Lindor, et al., 2000; Miozzo, et al., 1998; Pujol, et al., 2000; Sznajer, et 
al., 2008; Tong, 1995; Wang, et al., 2003b; Volpi, 2004). Data for 202 RTS cases 
collected from literature was taken from (Vennos and James, 1995) and the data of 
41 RTS patients from (Wang, et al., 2001). 
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2.5 Baller-Gerold syndrome 
The whole existence of Baller-Gerold syndrome (BGS, MIM 218600) as a separate 
entity has been widely debated (Cohen and Toriello, 1996; Huson, et al., 1990). The 
narrow definition of Baller-Gerold syndrome is craniosynostosis with radial ray 
defect, but there are patients with a more complex phenotype (Galea and Tolmie, 
1990). Only about 20 cases have been described and there is a marked genetic 
heterogeneity because some of the patients first diagnosed as BGS have on further 
studies been found to have Fanconi anaemia, Roberts syndrome, VACTREL 
association or Saethre-Chotzen syndrome (Farrell, et al., 1994; Huson, et al., 1990; 
Rossbach, et al., 1996; Seto, et al., 2001). It has been also shown that valproate 
exposure during the fetal stage can lead to the BGS phenotype (de Oliveira, et al., 
2005). The genetic heterogeneity and phenotypic overlap with other syndromes 
makes the BGS diagnosis complicated. 
Subsets of patients with BGS have been found to have RECQL4 mutations, but these 
patients have a broader phenotype than the narrow definition of BGS and phenotypic 
overlap with RTS was noted (Megarbane, et al., 2000). In addition to 
craniosynostosis and radial ray defect the patients suffered for example from pre- 
and postnatal growth retardation and poikiloderma (Megarbane, et al., 2000; Van 
Maldergem, et al., 1992).  
2.6 RECQL4 gene and protein 
The RECQL4 gene was cloned in 1998 and it was found to be a member of the RecQ 
gene family (Kitao, et al., 1998). RECQL4 is located at the proximal end of the long 
arm of chromosome eight, 8q24.3 and its genomic size is about 6.4 kb and its coding 
sequence is 3.6 kb (Kitao, et al., 1999a). RECQL4 is composed of 21 exons and 20 
introns that are relatively small. In fact 13 out of the 20 introns are less than 100 bp 
long. Deletions in these small introns can lead to a missplicing of mRNA because 
the intronic size becomes too small for efficient splicing even if the required 
consensus sequences remain intact (Wang, et al., 2002). In RECQL4 intronic 
deletions ranging from 11 to 25 bp have been reported in several cases (Balraj, et al., 
2002; Broom, et al., 2006; Wang, et al., 2003b; Wang, et al., 2002). Schematic 
drawings of the RECQL4 gene presented in Figure 2a.   
RECQL4 has a wide expression pattern since it was present in all studied organs 
with the highest expression in thymus and testis (Kitao, et al., 1998). In 
synchronized cells the expression levels started to rise at the G1/S phase and were 
highest in the S phase of the cell cycle (Kitao, et al., 1998). In another study 
transformation of endothelial cells and fibroblasts with SV40tsT increased the 
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RECQL4 expression (Kawabe, et al., 2000). When B-lymphoplastoid cells were 
transfected with Epstein-Barr virus the expression of RECQL4 started to rise when 
the cells proceeded to the S phase and the levels were highest in actively diving cells 
in the S, G2 and M phases (Kawabe, et al., 2000). The phorbol myristic acetate 
(PMA) stimulation of these cells lead to the increase of RECQL4 in later stages of 
the stimulation suggesting a role for it in DNA replication (Kawabe, et al., 2000).  
RECQL4 encodes the RECQL4 protein of 1208 amino acids (Figure 2b). The 
localization of the RECQL4 protein has been shown to be nuclear in several studies 
(Burks, et al., 2007; Kitao, et al., 1998; Macris, et al., 2006; Woo, et al., 2006; Yin, 
et al., 2004). However in some reports RECQL4 has been found also in the 
cytoplasm (Burks, et al., 2007; Petkovic, et al., 2005; Yin, et al., 2004). It was 
suggested that the different antibodies and methods used in these studies could 
explain the inconsistencies (Burks, et al., 2007). The role of cytoplasmic RECQL4 is 
not known, but it was proposed to have a nuclear export signal that would allow it to 
shuttle between the nucleus and cytoplasm (Burks, et al., 2007). The analysis of 
mutant RECQL4 constructs has revealed nucleolar localizations signal at amino 
acids 376-386 (Woo, et al., 2006). In another study the overlapping fragment at 
amino acids 364-492 was shown to contain nuclear localization signal in addition to 
nuclear retention signal (Burks, et al., 2007). The role of different cellular 
localization of RECQL4 protein is not yet understood. 
 
Figure 2. Schematic presentation of the RECQL4 gene and RECQL4 protein.  
A) The genomic structure of RECQL4. The exons 8-14 that contain the helicase 
domain are colored grey. B) The schematic structure of RECQL4 protein. The 
conserved regions that are found in helicases are marked with black boxes. Nuclear 
localization signals found in RECQL4 is marked with grey box.  
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2.6.1 RecQ gene family and helicases 
RECQL4 was named after E. coli RecQ protein because of the protein sequence 
similarity (Kitao, et al., 1998). E. coli RecQ has a role in conjugal recombination 
and it has helicase activity (Nakayama, et al., 1984; Umezu, et al., 1990). In humans 
there are five RecQ orthologs that are RECQL4 (Kitao, et al., 1998), RECQL 
(Puranam and Blackshear, 1994; Seki, et al., 1994), BLM (RECQL3, RECQ2) (Ellis, 
et al., 1995), WRN (RECQL2, RECQ3) (Yu, et al., 1996) and RECQL5 (Kitao, et al., 
1998) that share seven consensus domains common to the helicases (Kitao, et al., 
1998). In addition, they share other conserved domains found in RecQ proteins such 
as the RQC (RecQ conserved region) and helicase-and-ribonuclease D/C-terminal 
(HRDC) domains (Kitao, et al., 1998). The HRDC domain that apparently is needed 
for the binding to the nucleic acid substrate (Morozov, et al., 1997). The schematic 
presentation of human RecQ proteins is given in Figure 3. 
 
 
Figure 3. Schematic presentation of human RecQ proteins. The size of the 
polypeptide is given after its name. The conserved regions are marked in the 
diagram. Modified from (Harrigan and Bohr, 2003).  
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RECQL4 diverges most from the other long RECQ proteins since it lacks the HRDC 
domain present in other human RECQs and it has its acidic domain in its C-terminus 
whereas the other proteins have it in their N-terminal (Kitao, et al., 1998). Because 
of these differences it is proposed that RECQL4 might not have the same functions 
as the other RecQ proteins (Kitao, et al., 1998).  
Helicase proteins are able to unwind either DNA or RNA substrate by using NTP 
hydrolysis as their energy source. They share characteristic conserved nine motifs 
and are classified into subgroups by the level of the sequence conservation. The role 
of different kind of helicases and their function has been widely studied, for a 
review see (Ellis, 1997; Gorbalenya and Koonin, 1993; Hall and Matson, 1999). The 
function of some of the areas is known. For example domains I and II are also 
known as Walker A and B domains and play roles in nucleotide binding (Walker, et 
al., 1982). Mutational analyses of different helicases in several species give clues to 
the importance of the specific conserved sequences, for a review see (Hall and 
Matson, 1999). Hall and Matson (1999) stated that all the motifs take part in the 
ATP binding and or hydrolysis at some level and they are needed for the function of 
the helicase.  
All other human RecQ proteins - RECQL (Sharma, et al., 2005), BLM (Karow, et 
al., 1997), WRN (Gray, et al., 1997) and RECQL5 (Garcia, et al., 2004) - have 3’-
>5’ DNA helicase activity in contrast to RECQL4 (Macris, et al., 2006). In addition, 
WRN has exonuclease activity (Huang, et al., 1998). The RecQ proteins have 
several important roles such as DNA replication, recombination and telomere 
function in the maintenance of genomic integrity. Mutations in three of them 
RECQL4, BLM and WRN lead to recessively inherited syndromes. 
2.6.1.1. Bloom and Werner syndromes  
Mutations in BLM and WRN genes lead to Bloom (BLM, MIM 210900) (Ellis, et al., 
1995) and Werner (WRN, MIM 277700) (Yu, et al., 1996) syndromes, respectively. 
Both are rare autosomally recessively inherited conditions with a high cancer 
predisposition and features of progeria.  
Patients with Bloom syndrome are born small for their gestational age and a 
proportionate growth disturbance continues postnatally (Bloom, 1966). Patients are 
sensitive to sunlight and they show characteristic dermatological features such as 
telengiactasia and hypo- and hyperpigmentation. Patients have signs of the 
chromosomal instability such as spontaneous sister chromosome exchange possibly 
explaining their increased cancer risk. Males with Bloom syndrome are sterile and 
women have problems getting pregnant and their reproductive time is lower than 
unaffected women. Patients have increased risk to develop all kinds of malignancies. 
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An increased risk for colorectal cancer was reported among healthy BLM carriers, 
but the mechanism behind this phenomenon was not studied further (Gruber, et al., 
2002). It was proposed that either the haploinsufficient cells are not able to maintain 
the genomic integrity or that a loss of the intact second BLM allele in a cell line 
would lead to a colony of BLM deficient cells (Gruber, et al., 2002). 
Cells from BLM patients have a defect in the suppression of homologous 
recombination and thus a high rate of sister chromatin exchanges (SCE) in their 
chromosomes (Ellis, et al., 1995). BLM’s role in the recombination is important 
since homologous recombination is needed during the double strand break (DSB) 
repair (Chen, et al., 2003; Wu, et al., 2001). BLM deficient cells also give a clue to 
their role in the DNA replication since the replication intermediates start to 
accumulate into these BLM deficient cells (Lonn, et al., 1990). Its expression profile 
which shows its highest expression in the S and G2 phases predicts this (Ababou, et 
al., 2000) and BLM associates with the late replication foci (Bischof, et al., 2001). It 
is also needed for the relocalization of the RAD50/MRE11/NBS1 complex into the 
sites of the arrested replication fork (Franchitto and Pichierri, 2002).  
Werner syndrome is characterized by the growth disturbance due to the lack of 
growth spurt in their teens in addition to a stocky trunk and slender limbs 
(Thannhauser, 1945; Werner, 1904). Diabetes mellitus, scleroderma-like 
dermatological changes, cataracts, premature arteriosclerosis and subcutaneous 
calcification are common features. Patients have typical faces with beaked nose and 
their face is described prematurely aged with wrinkles and loss of subcutaneous fat. 
Patients are prone to develop sarcomas and they have marked chromosomal 
instability with deletions, translocations and inversions. Usually patients have 
several clonal cells in their blood or skin (Hoehn, et al., 1975). It has been shown 
that even though carriers of the WRN mutations are healthy they show signs of 
genetic instability with an increase risk for malignancies (Moser, et al., 2000).  
WRN is needed in homologous recombination (Saintigny, et al., 2002) and in 
nonhomologous end-joining (Chen, et al., 2003). It is needed in the sites of the 
arrested replication fork to bypass the DNA damage by homologous 
recombination (Baynton, et al., 2003). WRN’s role in solving the replication arrest 
was shown in studies with the hydroxyurea induced DNA damage (Constantinou, 
et al., 2000; Pichierri, et al., 2001). BLM and WRN have the ability to unwind the 
G4-DNA structures (Fry and Loeb, 1999; Sun, et al., 1998) which potentially give 
them the ability to unwind telomeric DNA. 
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2.6.2 Possible role and function of the RECQL4 protein 
As RECQL4 belongs to the RecQ helicase family it was proposed to have a helical 
activity. Unfortunately, the extraction of the protein has been difficult and several 
groups have failed to extract it (Plon and Wang, 2006; Stagljar and Dietschy, 2005). 
Finally, the helicase activity test showed that RECQL4 neither possesses helical nor 
translocase activities (Macris, et al., 2006; Yin, et al., 2004). The DNA dependent 
ATPase activity was shown in both studies (Macris, et al., 2006; Yin, et al., 2004). 
However, the exact role of the RECQL4 protein is still unknown and difficulties 
with protein extraction are very likely to contribute to this situation.  
Interactions of RECQL4 with the UBR1 and UBR2 ligases have been demonstrated, 
but the meaning of these interactions is unknown (Yin, et al., 2004). RECQL4 has 
been shown to partially colocalize with promyelotic leukaemia bodies (PML) and 
also partially colocalize with ssDNA regions after double strand breaks were 
introduced with etopocide (Petkovic, et al., 2005). Since RECQL4 can form a 
complex with Rad51 it has been proposed that RECQL4 has a role in the repair of 
the double strand breaks (DSB) lesions in cells (Petkovic, et al., 2005). Oxidative 
stress leads the RECQL4 to localize in the nucleoli (Woo, et al., 2006). The C-
terminal part of RECQL4 was suggested to interact with poly(ADP-ribose) 
polymerase-1 (PARP-1). PARP-1 protein works in maintenance of genomic 
integrity (Grube and Burkle, 1992). 
In Xenopus the RECQL4 homolog is known as xRTS (Sangrithi, et al., 2005). This 
protein is needed for initiation of DNA replication and the human RECQL4 can do 
this in cells depleted from xRTS (Sangrithi, et al., 2005). RECQL4 seems to be 
important for the ability of murine cells to proliferate by allowing DNA replication 
(Ichikawa, et al., 2002; Sangrithi, et al., 2005). As the cells from human RTS patients 
or from the mice models are able to proliferate it was proposed that the N-terminus is 
the critical part for RECQL4 function since none of the known patients with RECQL4 
mutations has truncating mutations in N-terminus of both of the alleles (Sangrithi, et 
al., 2005). In another study the N-terminus of Xenopus RECQL4 homolog was 
responsible for the replication activity (Matsuno, et al., 2006). They showed that xRTS 
is required for polymerase alpha to bind chromatin and that it is needed for the 
replication machinery assembly in Xenopus (Matsuno, et al., 2006).  
It is not know what happens to the mutated RECQL4 polypeptide in patient cells. 
However, it has been shown that some of the RECQL4 mutation bearing mRNAs 
become subject to nonsense mediated decay and a polypeptide is never produced 
(Beghini, et al., 2003; Sznajer, et al., 2008). In nonsense mediated mRNA decay 
premature stop codons are recognized and mRNA is degraded after its transcription 
(Losson and Lacroute, 1979). In Western blotting of proteins from RTS patient cells 
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RECQL4 was not detected (Broom, et al., 2006). This can be either due to a 
complete lack of the RECQL4 protein or that it is produced in such low amounts 
that it is not detected in Western blotting. 
When cells from RTS patients with the RECQL4 mutations were treated with H2O2 
they were found to be hypersensitive for the stress and damage caused by oxidative 
species (Werner, et al., 2006). The cells had reduced growth because of proliferation 
failure due to a decreased DNA synthesis rate (Park, et al., 2006; Werner, et al., 
2006). The UV-induced damage leads to the transient DNA synthesis inhibition in 
the RTS patient cells with RECQL4 mutations (Park, et al., 2006). Wild type 
fibroblasts had a 24 hours arrest compared to eight hours in the RTS patient cells 
indicating that the cells would be defective in the S-phase arrest and that RECQL4 
has role in the S-phase arrest (Park, et al., 2006). Since the cells from Bloom 
syndrome patients did not show this feature it is possible that RECQL4 has a unique 
function not seen in other RecQ proteins (Park, et al., 2006). Hydroxyurea (HU) 
causes the replication fork arrest in normal cells, but cells from RTS patient showed 
defect in S-phase arrest (Park, et al., 2006). Since the RECQL4 defective cells have 
problems either with the maintenance or the induction of the replication fork arrest 
RECQL4 could have a role in signalling of the DNA damage and/or repairing of it 
(Park, et al., 2006). The RECQL4 transcription is shown to be downregulated by p53 
in the G1 arrested cells (Sengupta, et al., 2005). One possible explanation for this 
phenomenon could be that the repression system might function as a back-up system 
in the surveillance of genomic stability (Sengupta, et al., 2005). 
However, the exact role of human RECQL4 is still unknown. Circumstantial 
evidence shows that it could have role in the DNA repair and replication and in that 
way in the maintenance of the genomic integrity  
2.6.3 Recql4 deficient mouse models 
Human RECQL4 and mouse Recql4 are 85.8% homologous in the protein level with 
three gaps in the alignment (Ohhata, et al., 2000). Two of them are 11 and 14 amino 
acid sequences that are missing from the mouse sequence. The largest gap size of a 
35 amino acids is located in the area of human exon seven where human amino acid 
sequence has the gap (Ohhata, et al., 2000).  
In total three different Recql4 deficient mouse models have been generated. The first 
was generated by Ichikawa and co-workers and it had its exons five to eight replaced 
by the knockout vector (Hoki, et al., 2003; Ichikawa, et al., 2002). No viable 
knockout mice were produced since this disruption of the Recql4 gene leads to the 
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death of embryos at 3.5-6.5 days after conception (Hoki, et al., 2003; Ichikawa, et 
al., 2002). Unfortunately, the original article is in Japan (Ichikawa, et al., 2002).  
In the second mouse model exon 13 of the Recql4 gene was deleted with an 
insertion of a targeting vector (Hoki, et al., 2003). In the mRNA level this leads to 
the inframe deletion of exon 13 and at the protein level it deletes 90 amino acids 
from the helical domain. In the mRNA level a substantial amount of truncated 
product containing exons 1 to 12 was found. The viability of these mice was 
extremely poor since only about 5% of the knockout mice survived more than two 
weeks after the birth. The embryogenesis of the-/- mice was not disturbed and the 
lethality of the mice was postnatal. The mice were smaller than their littermates and 
developed hair loss and lesions on the skin. Hypoplasia was noted in several tissues 
such in bone, teeth, the villi of the small intestine and shrunken thymuses. Hoki and 
co-workers (2003) also state that the mice did not develop cataracts, as was in fact 
expected given the RTSII phenotype. 
Interestingly in another study all the -/- mice (Hoki, et al., 2003) died before 
embryonic day 10 (Yang, et al., 2006). Because of this the research group used +/- 
mice that were heterozygotes for the mutant allele. Heterozygote mice were noted to 
have decreased bone mass. At the age of two months +/- heterozygote mice had 
fewer osteoprogenitor cells in their bone marrow when compared to wild type mice. 
Recql4 protein was found in cells that were actively forming bone. For example in 
tibia the protein was abundant in chondrocytes of the growth plate, osteoblasts lining 
the trabecular surface and bone lining cells of endocortical surface. In osteocytes 
that are fully differentiated bone cells the protein was not detected. In the mouse 
osteoprogenitor cells MC3T3.E1 the overexpression of the Recql4 leads to the 
increased cell proliferation rate and the silencing of Recql4 by siRNA to a decrease 
in the cell proliferation (Yang, et al., 2006).  
The third mouse model had a better survival rate since 84% of the knockout mice did 
survive to adulthood (Mann, et al., 2005). In this case the Recql4 gene was disrupted 
by replacing the exon 9 to 13 by the PGKHprt mini gene that leads to the truncated 
mRNA containing exons 1 to 8. The phenotype of these mice was slightly different 
from the other mouse model. They did not have growth defect, but had more dramatic 
skeletal phenotype with palatal defects in all mouse studied and polydactyly in hind 
limbs in some of them. These mice had hypo-/hyperpigmentation in their tails. From 
100 analyzed -/- mice five developed cancers, three lymphomas and two 
osteosarcomas. Aneuploidy was noted in the mice and it was thought to be the major 
contributor to the cancers. The -/- mice were crossed with ApcMin/- mice to generate a 
sensitized background in order to study the cancer susceptibility for gastrointestinal 
tumours. All the Recql4 deficient Recql4-/-, ApcMin/- mice developed intestinal tumours 
compared to 50% in Recql4+/-, ApcMin/- (Mann, et al., 2005). 
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3 AIMS OF THE STUDY 
Aims of this study were to: 
1. Identify the gene and mutation(s) behind RAPADILINO syndrome. 
2. Study the RECQL4 gene from patients with suspected RAPADILINO, Rothmund-
Thomson and Baller-Gerold syndromes. 
3. Define the clinical phenotype of patients with RECQL4 syndromes. 
4. Make a genotype-phenotype correlation for RECQL4 syndromes. 
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4 PATIENTS, MATERIALS AND METHODS 
4.1 Patients and DNA samples 
Originally, we had DNA samples from nine Finnish RAPADILINO families 
containing 11 patient samples for the initial genome-wide scan. In addition, we had 
15 parental samples and 11 samples from unaffected siblings. When the mutations 
were found from the RECQL4 gene we could screen additional RAPADILINO 
samples from patients or families. From one family we could not obtain the patient 
sample (r704), but we had parental samples, which were used to test the mutations. 
In family r1000 patient r1003 had a sibling who was deceased at the age of one year 
and she was suspected to have RAPADILINO syndrome. A paraffin embedded 
block was obtained for DNA extraction from patient r1203 and from the deceased 
sibling of patient r1003.  
We obtained 274 Control DNA samples for estimation of the carrier frequency of 
the Finmajor mutation. In addition, we obtained 262 samples from patients who 
suffered from unexplained growth disturbance either in the form of pre- or postnatal 
growth retardation. 
Clinicians outside Finland referred to us 33 index cases with two additional affected 
siblings in two families. In addition, we obtained 33 DNA samples from the parents 
and unaffected siblings of 15 families. We had no clear clinical data available about 
the patients and they were referred to us as having one of the RECQL4 spectrum 
diagnoses. The clinical criteria used were very variable depending on the clinician’s 
knowledge about RECQL4 diseases. Some of the patients were claimed to have mild 
or atypical features. More thorough clinical data was requested from all the 18 non-
Finnish patients with known RECQL4 mutations and this was obtained in 17 cases 
(Publications II, III, IV). 
The study was approved by the Ethical Committee of the Joint Authority for the 
Hospital District of Helsinki and Uusimaa. 
4.2 Cell lines  
Blood samples for lymphocyte extraction were requested from patients’ r303, r304, 
r405, r504, r904 and r1003. Lymphocytes were collected from the fresh blood 
sample taken into a 10 ml heparin containing tube. In addition, we obtained skin 
biopsies from patients’ r303, r304, r405, r605 and r1003 for fibroblast cell cultures.   
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4.3 Methods presented in articles 

Materials and methods used in this thesis are presented in the original publications. 
  
Method Article 
Minisequencing I 
Sequencing of the RECQL4 I, II, III, IV 
In situ hybridisation I 
Cell cultures  I 
mRNA studies I 
Genotyping I 
Collection of clinical data IV 
Bioinformatics I, II, III, IV 
4.4 Other methods 
4.4.1 Recombination and physical map of markers adjacent to RECQL4 
To determine the location of the markers adjacent to the RECQL4 information of the 
markers D8S373, D8S1836 and D8S1925 with RECQL4 was collected from the 
UCSC genome database (genome.ucsc.edu/) where the latest March 2006 assembly 
was used. To determine the recombination map of the given makers information was 
collected from Marshfield clinic’s Centre for Human Genetics 
(research.marshfieldclinic.org/genetics/GeneticResearch/compMaps.asp). 
4.4.2 DNA extraction from paraffin embedded blocks 
DNA was extracted from two paraffin embedded tissue blocks by using a protocol 
modified from Fincka and co-workers’ (Finke, et al., 1993). Five m thick slices 
were cut from the paraffin block and about 30 of them were used in the DNA 
extraction. First paraffin was removed from the sample with Octane reagent (Flucka 
#74821). 1000 l of Octane was added to the tube containing the paraffin slices and 
it was vortexed for 10 seconds. 100 l of methanol was added and it was vortexed 
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again to dissolve the paraffin. The tube was centrifuged for two minutes at 13000 
rpm (Eppendorf centrifuge 5810R, rotor F45-30-11). The supernatant was discarded 
and 360 l proteinase K buffer (pH 8.0, 20 mg/ml proteinase K) was added and the 
contents of the tube was mixed by flicking. The solution was incubated in +55ºC and 
vortexed three times over 48 hours. 
After the incubation, the tubes were heated to +95ºC for 20 minutes and centrifuged 
for10 seconds with an Eppendorf centrifuge. A phenol-chlorophorm-isoamylalcohol 
mixture with the proportions 25:24:1, respectively was added the tubes and they 
were vortexed for one minute. The tubes were then centrifuged for five minutes at 
11000 rpm with an Eppendorf centrifuge at +4ºC. The upper phase of the solution 
was then transferred to a new Eppendorf tube. 700 l of cold (-20ºC) 100% ethanol 
was added slowly to the tube. After this 400 l of 0.2 M sodiumacetate solution was 
added. The DNA was precipitated by flicking the tube and it was inverted 15 times 
to make sure the precipitation was complete. The solution containing the 
precipitated DNA was chilled for 30 minutes at -80ºC and then centrifuged for 30 
minutes in +4ºC at a speed of 11000 rpm in an Eppendorf centrifuge. The 
supernatant was discarded and 1 ml of cold (-20ºC) 70% ethanol was added to wash 
the DNA. The tube was then centrifuged as in the previous step. The washing of the 
DNA pellet was repeated with another 1 ml of ethanol and the centrifugation was 20 
minutes in this second washing step. The supernatant was discarded and the DNA 
was air dried. The DNA was dissolved in 100 l water and its concentration was 
measured using Nanodrop. 
4.4.3 Cloning of the RECQL4 constructs 
The human and mouse RECQL4 genes were cloned into the pEGFP and pCMV-Tag 
expression vectors. For the cloning of human full length wild type and mutant ex7 
RECQL4 DNA fragments the pEGFP vector was cut open with XhoI and SalI 
restriction enzymes and pCMV-Tag with EcoRI and SalI restriction enzymes. For 
the cloning of mouse Recql4 the pEGFP vector was cut with EcoRI and ApaI 
enzymes and pCMV-Tag with EcoRI and SalI enzymes. Enzymes were from 
Amersham Biosciences (ApaI # E1005Y, EcoRI #E1040Y, SalI # E1080Y and XhoI 
# E1094Y). In all cases either the GFP or FLAG-tag were incorporated into the N-
terminus of the polypeptide. The cloned DNA fragment was amplified with primers 
containing a restriction site for enzymatic cleavage of the PCR product. Primer 
sequences are given in Table 3. 
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Table 3. Primers used for human and mouse RECQL4 cloning. 
Species Enzyme  Primer sequence 
Human 5’ XhoI AATTCCTCGAGATGGAGCGGCTGCGGGACGTGCG 
Human 5’ EcoRI ATCTCGAATTCATGGAGCGGCTGCGGGACGTGCG 
Human 3’ SalI AATTCGTCGACTCAGCGGGCCACCTGCAGGA 
Mouse 5’ EcoRI 
ACTAGGAATTCATGGAGCGGCTCGCGACCGT 
Mouse 3’ ApaI 
AATTCGGGCCCTCATCGGCCTCTCAGCAGGA 
Mouse 3’ SalI 
AATTCGTCGACTCATCGGCCTCTCAGCAGGA 
 
The PCR procucts and vectors were digested with corresponging restriction enzymes 
according to the manufacturers’ instructions. Digested PCR product and vector were 
purified using QIAquick PCR Purification Kit (Qiagen #28104). The PCR products 
were ligated with their corresponding vectors with T4 DNA ligase (New England 
BioLabs #M0202S) according to manufacturers’ instructions. The ligated product 
was then transformed into E. coli bacteria and the cells were plated on ampicilling 
containing culture dish. Bacteria clones were picked from the culture dish and 
grown in ampicilling containing media. Plasmid DNA was extracted according to 
manufacturer’s protocol (Qiagen #12163). 
4.4.4 Antibody production  
Polypeptides of 15 amino acid from human and mouse RECQL4 sequences were 
selected from antibody production in rabbits. Human polypeptide was 
EKRRWNEEPWESPAQ and mouse YYFEEEEEEEETMTD. Both of the 
polypeptides had MAP4 conjugates in their C-terminuses and they were produced 
by Invitrogen. In both cases 2680 g of polypeptide was dissolved to prepare the 
antigen solution. Human polypeptide was dissolved into sterile water to obtain a 
1670 g/ml concentration. Mouse polypeptide was first dissolved into 20 l of 
DMSO and then 1580 l of sterile water was added. Two rabbits were immunized 
with each polypeptide so four rabbits were used in total. Before the first inoculation 
0-blood samples from each rabbit was taken for a reference sample. The animals 
were inoculated four times with 400 l of antigen solution in addition to 400 l of 
adjuvant. Ten days after the fourth inoculation the animals were sacrificed and blood 
was drawn. The next day the blood was centrifuged and serum was stored at -20ºC. 
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The number of National Public Health Institute permission for animal tests was 
200132. Animal care and handling were at all times consistent with the guidelines 
set out in the National Research Council’s guide for laboratory animal care and use. 
4.4.5 Transfection of the cells 
HeLa, COS-1 and HEK cells were transfected with pEGFP-Recql4, pEGFP-
RECQL4 wild type, pEGFP-RECQL4 ex7, pCMV-Tag-Recql4, pCMV-Tag-
RECQL4 wild type and pCMV-Tag-RECQL4 ex7 expression vectors. In addition, 
cells were transfected with empty pEGFP and pCMV-Tag vectors for the reference. 
The transfections were done according to the manufacturer’s protocol by using 2 g 
of vector with 3 l of FuGENE HD (Roche, #04883560001). In double transfections 
with wild type and ex7 mutant constructs 1 g of each construct was used. The 
cells were grown in 6-well plates with four glass slides on each well. After 24 hours 
post transfection the media was discarded and the wells were washed twice with 
PBS. The cells were fixed with 4% paraformaldehyde in PBS for 15 minutes and 
then the fixing media was replaced with PBS.  
4.4.6 Immunostaining 
The basic protocol for immunofluorescence staining was the following: The primary 
and secondary antibodies were different in various stainings. The PFA fixed cells on 
the glass slides were washed and incubated with PBS twice for 5 minutes. Cells were 
permeabilized with 0.1% Triton-X, 0.5% BSA in PBS for 15 minutes at room 
temperature. The cells were again washed twice for 5 minutes with PBS and blocking 
was performed with 0.5% BSA in PBS for 30 minutes. Primary antibodies were 
diluted into the blocking buffer at the following proportions 1:100 (rabbit 0-blood), 
1:250 (rabbit antiserum for human and mouse polypeptides) and 1:500 (mouse anti-
FLAG M2 antibody for pCMV-Tag vector, Stratagene #200472-21). Primary antibody 
was left on the cells for one hour after which the cells were washed three times with 
blocking buffer. Secondary antibodies were left on the cells for 40 minutes and the 
reaction was done in the dark. The secondary antibodies were diluted into the blocking 
buffer with a 1:200 concentration and the following antibodies were used: FITC 
conjugated Goat Anti-Rabbit IgG (Jackson Immuno Research laboratories #111-096-
003), FITC-conjugated Goat Anti-Mouse IgG+IgM (Jackson Immuno Research 
laboratories #115-096-044), TRITC-conjugated Goat Anti-Mouse IgG (Jackson 
Immuno Research laboratories #115-026-003) and TexasRed dye conjugated Goat 
Anti-Rabbit IgG (Jackson Immuno Research laboratories #111-075-144). Because 
pEGFP expression vector has GFP attached to the expressed protein it does not need 
to be stained with antibodies. In double transfections and stainings where the pEGFP 
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expression vector was used red secondary antibody against primary anti-FLAG 
antibody was also used. In this way it was possible for us to distinguish the different 
antibodies from each other. After the secondary antibody the cells were washed twice 
for 5 minutes with PBS and once with milliQ water. Glass slides were mounted with 
Immu-Mount (Thermo #9990402). 
4.4.7 Confocal microscopy 
The cells were microscoped using a Leica DMRXE confocal microscope. Leica 
confocal software was used for taking of the pictures and the light intensity was kept 
the same while taking the pictures. The pictures were then processed with the 
CorelDRAW 12 program to add the scale bars and crop the pictures. Scale bars 
representing 20 m were added to all pictures. Finally the pictures were opened in 
the Microsoft Office Picture Manager and the intensities of the pictures were 
autocorrected. 
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5 RESULTS AND DISCUSSION 
5.1 Genotyping (I) 
The whole genome scan was initially performed with 257 markers by using nine 
RAPADILINO families (see Section 4.1.), but no clear linkage peak was found. The 
scan marker D3S2398 in chromosome 3q28 gave LOD score 1.68, but the 
Transmission disequilibrium test - likelihood ratio test (TDT-LRT) value was 
0.1065, which did not speak in favour of a true linkage. The observation by Dr. 
Robin Winter (Institute of Child Health, London, UK) that Rothmund-Thomson and 
RAPADILINO syndromes could be overlapping prompted us to study the 8q24.3 
area which contained the RECQL4 gene that was known to be mutated in 
Rothmund-Thomson syndrome (Kitao, et al., 1999b). The flanking markers 
D8S1836, D8S373 and D8S1925 were used to study whether Finnish 
RAPADILINO patients share a common haplotype in this area. The LOD scores for 
these markers were 1.98, 2.28 and 2.12, respectively with the corresponding TDT-
LRT values 0.0628, 0.0033 and 0.0002. Surprisingly, several different haplotypes 
were observed in this 2.4 Mb area. Haplotype 18-7-6 was the major haplotype found 
in the families.Two completely different haplotypes were found from another 
chromosomes in families 3 and 4. The marker D8S272 was the last marker before 
telomere of the 8q chromosome in the original scan. This marker is only 6 Mb away 
from the marker D8S1836, but no evidence of linkage was found with this or any 
other markers further away.  
The studied area of chromosome 8 is interesting since the physical order of the 
markers in the genome is - centromere-D8S1836-D8S373-D8S1925-telomere - but 
D8S373 and D8S1836 change places when the recombination map is studied. The 
area is 3.43 cM long when the average of both sexes is taken into account, but in 
females the distance between these markers is zero and in males 7.09 cM. This 
phenomenon of females having less recombinations in the telomeric end of the 
chromosome is present in all human chromosomes (Broman, et al., 1998). The 
lengths of male and female recombination maps differ from each other and in human 
the female map is 223.72 cM long and in males 113.05 cM when the sex average is 
167.90 cM. The sizes in base pairs and cM are shown in more detail in Figure 4. 
There are two possible explanations for the very small shared haplotype. Either the 
mutation is very old or the haplotype became smaller when repeated recombinations 
degraded the ancestral chromosome or this chromosomal area is a recombination hot 
spot. 
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Figure 4. Schematic representation of chromosome 8 and the region containing the 
RECQL4 gene and the markers D8S1836, D8S373 and D8S1925. The telomere of 
chromosome 8 is marked with a black dot. The distances between the markers and 
RECQL4 are given in base pairs in the physical map (A) and in cM in the 
recombination map (B). 
It is interesting that the common haplotype in RAPADILINO patients was so short 
and not constant in all studied families. This factor contributed to the fact that no 
linkage was found in the initial linkage analysis. The linkage could have been found 
if the second round of genome-wide scans had been performed since marker 
D8S373 was in that marker set. Even though the haplotype around the RECQL4 
gene was small, one could still assume that there was a common founder mutation 
behind the haplotype. In the Finnish disease heritage the founder mutations are 
commonly referred as Finmajor mutations. All the chromosomes shared the allele 6 of 
marker D8S1925. The haplotypes found in the patients and their parents are shown 
in Figure 5. Haplotype data from patient r903 was not available. 
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Figure 5. Observed haplotypes of the RAPADILINO patients and their parents. The 
haplotype contains data from three different markers and their order is D8S1836, 
D8S373 and D8S1925 from up to bottom. The RECQL4 gene is marked with a 
horizontal line between the markers D8S373 and D8S1925.  
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The birthplaces of the grandparents of the patients have two concentrations - one in the 
Savo region and another in Ostrobothnia. The birthplaces of grandparents in 11 
families are shown in Figure 6. One has to bear in mind that in recessive inherited 
condition only half of the grandparents actually carry the mutation so the dots in 
Figure 6 do not actually present the mutations. Some concentration of the birthplaces 
of the patients’ grandparents can be seen. Genealogical studies showed that patients in 
two families have a common ancestor when going back six generations. Their 
common ancestors were born in the beginning of the 19th century (Mentula, 2002). 
From the map it can be assumed that the Finmajor mutation could be new since most of 
the dots are found in the Savo area. In contrast the short haplotype speaks in favour of 
an old mutation, but the haplotype could have been also broken down just by chance 
e.g. if this chromosomal region is a recombination hot spot. 
 
Figure 6. The birthplaces of the grandparents in 11 Finnish RAPADILINO 
families.The line represents the division between early and late settlement areas. 
The early settlement area is the costal region of Finland and the late settlement  
area is the mainland. Modified from (Norio, 2003a). 
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5.2 Sequencing of the RECQL4 gene (I, II, III, IV) 
5.2.1 RECQL4 mutations in Finnish RAPADILINO patients 
In the sequencing analysis of the RECQL4 gene we found altogether five different 
mutations in the Finnish RAPADILINO patients (Publications I and IV). The 
g.2545delT mutation i.e. the Finmajor mutation was found in all patient samples either 
in a homozygous or heterozygous form. In total 83% of the RAPADILINO 
chromosomes carried the Finmajor mutation that destroys the splice site of intron 
seven and results in an inframe skipping of exon seven. This was shown by 
analyzing cDNA that was reverse transcribed from the patients’ mRNA. None of the 
healthy siblings or the parents had RECQL4 mutations in both alleles. 
Five compound heterozygote patients were found in four families. The second 
mutation was a unique truncating mutation in every family. In family 3 (patients 
r303 and r304), the second mutation was C>T transition that causes a premature stop 
codon p.Gln1091X (g.5721C>T). The mutation is located in exon 19. Another 
premature stop codon p.Arg1072X (g.5588A>T) was found in exon 18 in family 4 
(patient r405). In family 7 no patient sample (r704) was available, but we found one 
of the parents to carry the g.2545delT mutation and another parent carried a novel 
premature stop codon p.Tpr269X (g.1556G>A) in exon five. The fourth truncating 
mutation was found in patient r1203 and it was a two nucleotide deletion in exon 21. 
This g.6295delCG mutation causes a frameshift. All compound heterozygote 
families had their own minor mutation and thus no other common ancestral mutation 
was found. The mutations found in the Finnish RAPADILINO patients are shown in 
Table 4 and in Figure 7 (Section 5.2.3.).  
 
Table 4. Mutations found in the Finnish RAPADILINO patients. 
Mutation Outcome Site Found/Chromosomes 
g.1556G>A p.Tpr269X Exon 5 1/30 
g.2545delT Skipping of exon 7 Intron 7 25/30 
g.5588A>T p.Arg1072X Exon 18 1/30 
g.5721C>T p.Gln1091X Exon 19 2/30 
g.6295delCG Frameshift Exon 21 1/30 
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In family 10 two affected siblings were reported and the male patient r1003 was 
found to be homozygous for the Finmajor mutation. The phenotypes of the siblings 
have been previously reported (Similä, et al., 1983). Since the female sibling had 
died at the age of one year we obtained paraffin embedded tissue sample for the 
mutation analysis. We did not found any mutations and it seems that the female 
patient did not after all have the defect described in the report (unpublished data).  
Two samples from the heterozygous patients were analysed to determine what was 
the fate of transcripts containing the g.5588A>T (p.Arg1072X) and g.5721C>T 
(p.Gln1091X) mutations since some of mRNAs containing premature stop codons 
are subject to a nonsense mediated mRNA decay. However, transcripts from both 
alleles were found in these two mRNA samples. Unfortunately, cell lines from 
patients r704 and r1203 were not available, but we had a cell line from the parental 
sample of r704 that was known to carry the g.1556G>A (p.Tpr269X) mutation. The 
cDNA fragment containing the g.1556G>A (p.Tpr269X) mutation was analyzed and 
heterozygosity for the mutation was found indicating that the mutation bearing allele 
is present in the mRNA level and not degraded in the cell.  
5.2.2 Minisequencing of controls and patients with pre- or postnatal 
growth retardation  
The estimation of the carrier frequency of the Finmajor mutation was analyzed from 
the sample of 274 healthy Finnish controls. Two heterozygotes were found and this 
gave a carrier frequency of one in 137 individuals. This is in concordance with the 
estimation of a new case approximately every second year. Yet this estimation is 
rough because of the small number of controls  
In addition, 262 DNA samples of children with unspecified pre- and postnatal 
growth retardation were screened to study if there were mildly affected 
RAPADILINO patients among them. We found one homozygote for the Finmajor 
mutation (patient r1103 is patient 7 in Publication IV), but no heterozygotes at all 
(unpublished data). This highlights the problem of the carrier frequency estimation 
in cases were the allele frequency is low. 
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5.2.3 RECQL4 mutations in Rothmund-Thomson, Baller-Gerold and 
non-Finnish RAPADILINO patients 
All together 35 DNA samples taken from non-Finnish patients with RECQL4 
spectrum syndromes diagnosis were referred to us. RECQL4 mutations were found 
in four RTS patients (Publications II and IV) and in five non-Finnish RAPADILINO 
patients (Publication IV). All these patients were index cases. Six BGS patients from 
four families were also found to have RECQL4 mutations (Publication III and IV). 
Clinical data from one patient (patient 16 in Publication IV) was not available thus 
the diagnosis is left open. All together 15 novel RECQL4 mutations were found in 
these patients (Publications II, III and IV, Figure 7). Two additional patient samples 
(patients 8 and 9 in Publication IV) were analyzed in another laboratory by Lisa 
Wang and Sharon Plon (mutation g.174del16 in Figure 8). Our laboratory has 
previously found two other novel mutations (g.3796T>C (p.Leu638Pro) and 
g.3506G>A (splice site)) (Sznajer, et al., 2008). The same p.Leu638Pro amino acid 
substitution was again found in a patient 16 in Publication IV. 
Five of these novel mutations were amino acid substitutions g.5435C>T 
(p.Arg1021Trp) in Publication II and g.2633C>T (p.Pro466Leu), g.3797T>C 
(p.Phe637Ser), g.4076T>C (p.Phe697Leu), and g.5525A>G (p.Ile1051Val) in 
Publication IV. The remaining ten mutations were truncating: g.1246C>T 
(p.Gln166X), g.3768delCGGG (frameshift), g.3770delGGAG (frameshift), 
g.4043G>A (splice site), g.4473C>T (p.Gln800X), g.4410del22 (frameshift), 
g.4536C>T (p.Gln821X), g.4494insCGGGG (frameshift), g.5446delA (frameshift) 
(all in Publication IV) and g.5428A>C (splice site) (Publication III). Most of the 
RECQL4 mutations are truncating and would thus lead to either loss of the protein or 
severely damage its function. The majority of the mutations have been found in the 
conserved helical region or in the latter third of the protein (Publication IV). Only a 
few mutations have been found from the first third of the RECQL4 gene. Some 
truncating mutations lead to a nonsense mediated decay (Beghini, et al., 2003; 
Sznajer, et al., 2008) and in one report mutated RECQL4 was not detected at the 
protein level (Broom, et al., 2006). Yet it is not known if the truncated RECQL4 is 
present in low levels in the cells. 
All the RECQL4 mutations identified in Studies I, II, III and IV in addition to earlier 
published RECQL4 mutations are presented in Figure 7. 
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5.2.4 The amino acid changes in the RECQL4 protein 
Putatively pathogenic amino acid substitutions reported in Publications III and IV 
are presented in Table 5. The possible effects of the amino acid substitutions were 
tested using the PolyPhen and SIFT prediction programs as described in Study IV. 
In addition, 12 RECQL4 homolog sequences from different species were aligned to 
find most conserved amino acids as described in study IV. Some of the results are 
contradicting as for example p.Pro466Leu and pPhe967Leu are predicted to be 
probably damaging by Polyphen as they change a rather conserved amino acid. Yet 
the SIFT predicts that these amino acid changes do not to affect protein function. 
The prediction of the amino acid change effect is difficult because of the lack of a 
3D structure for RECQL4. Nor is there information about the interactions between 
RECQL4 and other proteins. In two cases p.Leu638Pro and pArg1021Trp the 
change to different type of amino acid could explain the deleterious effect to the 
protein. Proline is a ring structured amino acid and can potentially disrupt the 
polypeptide 3D structure. Tryptophan is the biggest amino acid and thus can disrupt 
the protein 3D structure. 
 
Table 5. Putatively pathogenic amino acid substitutions in RECQL4 (Publications 
III and IV). 
PolyPhen SIFT  
Mutation 
 
Syndrome Score Pred. Score Pred. 
 
Conservation 
p.Pro466Leu RAPADILINO 2.401 ** 0.28 - 9/12 
p.Phe637Ser RAPADILINO 2.122 *** 0.04 + 7/12 
p.Leu638Pro RTS 2.110 *** 0.00 + 11/12 
p.Phe697Leu RAPADILINO 2.001 *** 0.26 - 11/12 
p.Arg1021Trp RTS & BGS 0.558 * 0.01 + 4/9 
p.Ile1051Val BGS 0.119 * 0.70 - 6/11 
PolyPhen predictions are * Benign ** Possibly damaging *** Probably damaging. 
The cut off value for SIFT score is <0.05, + predicted to affect protein function, - 
predicted to be tolerated. Conservation is the number of same amino acids 
compared to all amino acids in a given certain position in the RECQL4 homolog 
alignment.  
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In the alignment human RECQL4 protein was found to share similarities in the 
helical domain of RECQL4 of different species (data not shown). The conserved 
region in the helical domain is located between amino acids 492 to 749. In the 
alignment the human RECQL4 protein shared 51 identical and 31 similar amino 
acids in the region that included human RECQL4 sequence from amino acids 477 to 
720. The homology between different proteins would have been higher if more 
distant sequences had been omitted from the alignment.  
5.3  Phenotypes of RECQL4 syndrome patients and the genotype-
phenotype correlation (I, II, III, IV)  
Clinical data was collected from two Finnish (patients 6 and 7 in Table 6) and 13 
non-Finnish patients with the diagnosis of RAPADILINO, RTS or BGS 
(Publications II, III and IV). In addition, medical records were collected also from 
the all other Finnish RAPADILINO patients in order to study their cancer status 
(Publication IV).  
Table 6 shows the clinical findings in 15 patients with the RECQL4 mutations. 
Patients 1-13 are in the same order as they appear in the original Publication IV 
(Table 3). Data concerning patients 14 and 15 in Study IV was omitted because of 
the large amount of the clinical data was not available as pregnancies were 
terminated. Patient 14 in Table 6 is the patient from the original Publication II. 
Patient 15 in this same table is the patient four of family 1 (Publication III). Clinical 
findings from three other affected siblings from this same family were left out 
because the first patient (patient 1, family 1) died immediately after the birth. Two 
subsequent pregnancies with affected foetuses were terminated. Patient 16 in Table 
6 is the index patient of family 2 (Publication III). As seen in the table no patient has 
all the symptoms described. 
Study of the clinical findings is important since the phenotype is complex. The lack 
of cataract in human RTS cases was considered peculiar. This lack of cataract was 
also mentioned in the report of the Recql4 deficient mouse model (Hoki, et al., 
2003). Our studies (Publications I, I, III, IV) show that cataracts are not present in 
RTS patients with the RECQL4 mutations and thus should not be considered as an 
important diagnostic criterion. 
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Table 6. Clinical findings in 15 patients with RECQL4 spectrum syndromes. 
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Diagnosis 
A A A A A A A B B B B B C B C C 
Poikiloderma 
- - - - - - - + + + + + + + + + 
Short stature >-2SD    
+ + + + + + + + + + + + + + + + 
Craniosynostosis 
- - - - - - - - - - - + + - + + 
Brownish spots 
- - + + - + + - - - + - - - - - 
Thumb a-/hypoplasia
+ + + + + + - + + + + - + + + + 
Radial a-/hypoplasia
+ + + + + + - + + + + - + + - + 
Patellar a-/hypoplasia
+ + + + - + - + + + + - - + + + 
Palatal defect 
+ - + + - + - + + + - + - + - + 
Osteopenia* 
- - - - - - - + + - + - + - - - 
Malignancy  
- - - - - L O - - - - - - - - - 
Diarrhoea 
+ + + + + + + + + + + - - + - - 
Feeding problems 
- + + - + - - + + + + + + - + + 
Hearing problems  
+ - - - - - - + + - - - + - - - 
Alopecia, hairloss  
- - - - - - - - - - + + + + - + 
Joint dislocations 
+ - + - - - - - - - + + + - - - 
Gender 
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Diagnosis; A RAPADILINO syndrome, B Rothmund-Thomson syndrome, C Baller-
Gerold syndrome. 
* Confirmed osteoporosis in patient 14. L Lymphoma, O osteosarcoma 
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RTS is phenotypically variable syndrome. Even when the patients with the RECQL4 
mutations are classified into their own subgroup a great clinical variability can be 
seen (Hilhorst-Hofstee, et al., 2000; Sznajer, et al., 2008). Some of the patients show 
very severe bone malformations when others have none or subclinical 
malformations. Based on clinical findings the distinction of patients who would be 
likely to carry RECQL4 mutations is difficult because the symptoms are unspecific. 
In some cases RECQL4 mutations are not found even though the phenotype and 
clinical findings suggest diagnoses of RECQL4 syndromes.  
BGS variability can be explained by the small number of patients and because the 
phenotype has similarities with other syndromes. It is still an open question whether 
BGS and RTS are in fact the same phenotype because craniosynostosis has been 
found in both of them. Patient 12 has the diagnosis of RTS even though 
craniosynostosis is present. Mutations found in RTS and BGS patients are mainly 
truncating mutations. The RTS patient in Publication II shares exactly the same 
combination of mutations as BGS patients from family 1 (Publication III). These 
patients were found to be compound heterozygotes for truncating g.2886delT 
mutation and for g.5435C>T transition that leads to the p.Arg1021Trp amino acid 
substitution. In family 1, the index patient died immediately after the birth and two 
following pregnancies with affected foetuses were terminated. Detailed clinical data 
is thus available only from patient 4. The major phenotypic difference between these 
patients is the presence of craniosynostosis in the BGS patients.  
A total of 15 RAPADILINO patients are known in Finland. No other patients have 
been found even though a search was made of the birth malformation registry. We 
have noticed that like in RTS the RAPADILINO phenotype can have different levels 
of severity. The first patients assigned with RAPADILINO diagnosis were severely 
affected because the strict diagnostic criteria were used to find patients who would 
belong to same entity. Later more patients have come to our attention and two of 
them have a very mild phenotype. One patient with mild symptoms was diagnosed 
because he had an older affected sibling. Another RAPADILINO patient was found 
from a group of patients with pre- and/or postnatal growth retardation. He would not 
have been suspected to have RAPADILINO syndrome without the RECQL4 
mutation screening. The only dermatological finding in RAPADILINO patients is 
hyperpigmentation that resembles irregularly shaped café-au-lait spots. One mildly 
affected patient has plenty of these café-au-lait spots and they follow the patterning 
of the lines of Blashchko. These cells probably present a cell clone where the change 
leading to this hyperpigmentation occurred during embryogenesis and thus the lines 
of Blashcho have become visible. This same phenomenon is seen in a RTS patient 
(Broom, et al., 2006). RAPADILINO phenotype is characterised by growth 
retardation, radial ray and patellar defects, diarrhoea and feeding problems, joint 
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dislocations and high arched or cleft palate (Publications  I and IV). The phenotype 
of Finnish RAPADILINO patients is summarized in Table 2 and in Publication I 
(Table 1). When the phenotypes of Finnish RAPADILINO patients (patients 6 and 7 
in Table 6) is compared to the phenotypes of RTS and BGS patients in the same 
table the apparent differences are the lack of poikiloderma, craniosynostosis, 
alopecia, loss of eye brows and eye lashes in the RAPADILINO patients. Otherwise, 
the syndromes have very similar and overlapping clinical findings. This finding 
suggests the presence of modifying effects since the clinical findings in RECQL4 
syndrome patients are variable and some patients are very mildly affected. 
5.4 Cancer predisposition in RECQL4 syndromes 
Cancer predisposition in RECQL4 syndromes was initially thought to be restricted to 
osteosarcoma since in RTS this was the only malignancy reported in patients with 
RECQL4 mutations and only isolated reports about other malignancies were 
reported in unspecified RTS patients. The osteosarcoma incidence in RTS varies 
between studies and when we combined published data with our clinical data 
(Publication II and IV) we found the osteosarcoma incidence to be about 43.6% 
among RTS patients (Publication IV). When the RAPADILINO and BGS patients 
were included the osteosarcoma incidence dropped to 30.6% (Publication IV). The 
reason why we found less osteosarcomas than previously reported is unknown. One 
explanation could be that patients in our studies (Publications I, II, III, IV) are still 
relatively young and they are still in the risk age.  
Initially, we considered RAPADILINO patients to have lower malignancy risk than 
RTS patients (Publication I), but this hypothesis has been proven wrong. We found 
two osteosarcoma cases among Finnish RAPADILINO patients (Publications I and 
IV). Both of these patients are homozygotes for the g.2545delT mutation that leads 
to inframe skipping of exon 7. Thus there is significant osteosarcoma risk associated 
with all RECQL4 mutations not just to the truncating forms (Wang, et al., 2003b). 
Interestingly, in addition to two osteosarcomas four (r704, r903, r904 and r1203) out 
of the 15 Finnish RAPADILINO patients have developed lymphoma (Publication 
IV). We showed that the Finnish RAPADILINO patients also have an increased 
lymphoma risk not seen in other patients with RECQL4 mutations (Publication IV). 
The siblings r903 and r904 are both homozygotes for the g.2545delT mutation. 
Patients r704 and r1203 are compound heterozygotes for this mutation. The second 
mutation in patient r704 is g.1556G>A (p.Tpr269X) and in patient r1203 
g.6295delCG mutation. It is possible that the lymphoma risk is due to the 
g.2545delT Finmajor mutation and the missing of exon seven could have critical role 
in hematopoetic cells. As the RAPADILINO phenotype is rare in other parts of the 
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world and some of the patients are still young the overall lymphoma risk for 
RAPADILINO or RECQL4 syndrome patients is not yet known. However, the data 
collected from RTS patients does not show elevated lymphoma risk, but the reported 
clinical data has it flaws and it might not be complete. 
Osteosarcomas and lymphomas were seen in one of the Recql4 deficient mouse 
models (Mann, et al., 2005). In this model, the mutation generated truncated Recql4 
protein. It was encoded by first eight exons but lacked rest of the protein including 
the helicase domain that starts from exon 9. This type of truncating mutations are 
typically associated with osteosarcoma (Wang, et al., 2003b). However, this mouse 
model with the Recql4 truncating mutation developed also lymphoma which has not 
been seen in humans with this type of mutations. Even though human and mouse 
cancers are not identical it is interesting that lymphomas are not seen in all the 
RECQL4 spectrum syndromes. Time will show if the lymphoma risk stays 
associated only to the g.2545delT mutation leading to the skipping of exon 7. 
A reason for malignancies in RECQL4 syndromes is still unknown, but one 
explanation could be that RECQL4 seems to function as a caretaker gene and if the 
RECQL4 defect allows the cells to divide even when their genomic integrities have 
not been confirmed, aberrations in the genome could start to accumulate 
predisposing the RECQL4 deficient patients to malignancies. 
5.5 In situ hybridisation (I) 
The expression levels of mouse Recql4 were studied by using in situ hybridisation. 
The most prominent expression was detected in the chondrocytes of the developing 
bone and in the intestinal cell (see Figure 3 in Publication I). These findings fit 
nicely to the phenotypes of the Recql4 deficient mouse models (Hoki, et al., 2003; 
Mann, et al., 2005).  
Even though human and mouse protein functions may not be identical in situ 
hybridisation studies point to clinical findings seen in RECQL4 spectrum syndrome 
patients. The most prominent are the bone malformations and the high expression of 
the Recql4 in chondrocytes of the developing bone. Disturbed proliferation of the 
chondrocytes due to RECQL4 deficiency can explain the bone malformations in 
humans. The intestinal problems seen in many patients are in concordance with the 
high expression in the mouse intestine.  
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5.6 Cell lines (I, unpublished) 
When establishing Epstein-Barr virus (EBV) transformed cell lines from patient 
samples we found that the B-lymphocytes did not divide and grow at the same rate as 
control cells. Our first two attempts to grow EBV-transformed B-lymphocytes from 
patient r904 failed. After this the third sample from the same patient was left in to an 
incubator for weeks and we noticed some growth. This same procedure was followed 
in the treatments of five other samples (patients r303, r304, r405, r504 and r1003). In 
conclusion, the EBV-transformed B-lymphocyte cell line could be established if the 
cells were left to grow for weeks and eventually one could see typical cell clumps, but 
the growth rate of the culture remained slow. This phenomenon is apparently due to 
the RECQL4 defect in the lymphoblastoid cells as cells from the heterozygote parents 
(samples r401, r402, r702) grew without problems. This problem could be specific to 
the Finmajor mutation since the lymphoblastoid cell line can be generated from the RTS 
patients without problems (Plon and Wang, 2006). We are aware of only one other 
case where lymphoblastoid cell line was not able to be produced (Miozzo, et al., 
1998). This patient is homozygote for the g.2746del11 mutation. Apparently this 
problem is more common in Bloom syndrome where EBV-transformation of cells 
often fails (Kawabe, et al., 2000). Kawabe and co-workers (2000) stated that RecQ 
proteins are not essential for cell transformation (Kawabe, et al., 2000), but our 
findings with the observations from Bloom syndrome indicate that certain RecQ 
proteins might have role in it. 
5.7 RECQL4 constructs and the results of transfections 
(unpublished) 
Antibodies against human and mouse RECQL4 were tested in expression vector 
transfected cells with immunoflurescent staining. The rabbit antibody against mouse 
polypeptide gave staining with 0-blood that was supposed to be blank. Because of 
this the antibody was not used, as it was unspecific. Rabbit antibody against human 
RECQL4 was found to be specific when compared to 0-sample, but the amount of 
endogenous RECQL4 in HeLa cells was so low that it could not be detected reliably. 
For localization studies of the human wild type and mutant (ex7) RECQL4 HeLa, 
COS and HEK cells were transfected with GFP or CMV expression vectors 
containing either the wild type or mutant constructs. In total four different 
expression vectors were used. The transfection percentage was low with all the cell 
types and construct combinations. Usually the amount of transfected cells varied 
between 2 to 10%. In contrast for example when the cells were transfected with 
empty pEGFP vector all the cells were transfected and they expressed the 
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fluorescent GFP protein. In some transfected cells there was great overexpression of 
the RECQL4 protein that was seen as fluorescent aggregations in the cytoplasm. 
This phenomenon was especially strong in COS cells. The biggest problems were to 
find cells that were transfected but produced the protein in moderate levels to be 
able to see the assumed undisturbed localization of the protein. This generated 
another problem since taking pictures of the cells was somewhat difficult. The laser 
intensity was kept constant when taking the pictures and thus some of the 
moderately expressing cells were not properly visible against the black background. 
Because of this the pictures in Figure 8 were modified using Microsoft Office 
Picture Manager to autoformat the intensities. This of course changes the relative 
intensities of the pictures, but it was used to make the cells more visible.  
In conclusion, wild type RECQL4 had mainly nuclear localization and ex7 
RECQL4 had mainly cytoplasmic localization in all the cells and constructs studied. 
This misslocalization of the mutant allele could explain the RAPADILINO 
phenotype. The mutated RECQL4 protein can get into the nucleus, but because of 
the lack of a nuclear retention signal it is not kept there. The results had some 
variation between different cell lines. In COS cells there were visible dots that were 
due to a high overexpression which lead to the protein accumulation in the 
cytoplasm. In HEK cells the staining was rather uniform between the nucleus and 
cytoplasm with a wild type construct. Our findings were in line with the findings of 
previously published studies (Burks, et al., 2007). 
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Figure 8. RECQL4 mutant and wild type expression in transfected HeLa, COS and 
HEK cells. The white scale bar in each picture in 20 m. 
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6 CONCLUSION 
Mutations in the RECQL4 gene lead to RAPADILINO, Rothmund-Thomson and 
Baller-Gerold syndromes. Main common clinical findings are growth retardation, 
radial ray defect, gastrointestinal problems and elevated cancer risk, but 
poikiloderma and craniosynostosis separate them into distinct syndromes. 
RAPADILINO syndrome is a rare condition since only 20 RAPADILINO cases are 
known so far. However, RAPADILINO syndrome might be underdiagnosed since 
some of the patients have mild phenotypes that give no apparent clues to 
RAPADILINO.  
Most of the 48 RECQL4 mutations are truncating mutations, but the Finnish founder 
mutation is special since the mutation affects splice site and leads to inframe 
skipping of exon 7. The result of the mutation is a deletion of 44 amino acids from 
the RECQL4 protein. This part of the RECQL4 contains a nuclear retention signal 
and ex7 mutant protein was found to have cytoplasmic localization whereas the 
wild type protein was located in the nucleus. All the Finnish RAPADILINO patients 
are either homozygotes or compound heterozygotes for this mutation. 
RECQL4 mutations predispose patients to malignancies, which are osteosarcoma in 
RTS and osteosarcoma and lymphoma in RAPADILINO syndrome. Since all the 
patients with lymphoma are Finnish and carry the same mutation it is possible that 
the elevated lymphoma risk is due to this specific mutation (g.2545delT). Because 
the cancer risk is very high Finnish RAPADILINO patients need to be followed for 
possible lymphomas and osteosarcomas. This recommendation could be useful for 
all patients with RECQL4 syndromes before more follow-up data accumulates. 
It would be interesting to study if RECQL4 mutations in healthy carriers would have 
phenotypic effect for example elevated cancer predisposition. Studies have shown 
that RECQL4 mutations do not contribute to the sporadic osteosarcomas, but no 
studies concerning lymphoma patients have yet been done. 
Even though these RECQL4 syndromes are rare they give valuable information 
about the role of RECQL4 in bone development and cancer. It is interesting how 
different mutations in RECQL4 can lead to different phenotypes, but our 
understanding of this genotype-phenotype correlation is still in its early stages. 
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